Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Newswire

Comprehensive Real-Time News Feed for Teva Pharmaceutical Industries.

Results 1 - 20 of 649 in Teva Pharmaceutical Industries

  1. Natco Pharma, Orchid get a strong dose of Us Fda medicineRead the original story w/Photo

    4 hrs ago | The Indian Express

    Natco Pharma and Orchid Chemicals and Pharmaceuticals have received an adverse observation report, commonly known as Form 483, after inspections conducted in their manufacturing units earlier this year by the US Food and Drug Administration, according to documents reviewed by FE. Natco, which was in news for battling Teva Pharmaceutical Industries over the patent of the latter's multiple sclerosis drug Copaxone, was issued the Form 483 dated May 23 after a five-day inspection of its finished dosage facility located in Mahabubnagar district in Telangana.

    Comment?

  2. Summary of Research Progress Reported at the World's Largest MS MeetingRead the original story

    5 hrs ago | PressReleasePoint

    ... Synthon BV) reduced disease activity on MRI scans similarly to CopaxoneA (glatiramer acetate, Teva Pharmaceutical Industries Ltd). Participants were randomly assigned to receive GTR (20 mg/day injected under the skin), Copaxone (20 mg/day injected ...

    Comment?

  3. Successful Completion of Phase III Program for Teva's Reslizumab Two...Read the original story

    8 hrs ago | Hispanic Business

    The data demonstrated that reslizumab treatment resulted in significant improvement in lung function and asthma control measures and showed a safety profile comparable to placebo . Reslizumab treatment resulted in significant improvements in lung function versus placebo when administered to patients, with moderate to severe asthma with elevated eosinophils.

    Comment?

  4. Natco Pharma, Orchid Chemicals get a strong dose of Us Fda medicineRead the original story w/Photo

    11 hrs ago | Express India

    Natco Pharma and Orchid Chemicals and Pharmaceuticals have received an adverse observation report, commonly known as Form 483, after inspections conducted in their manufacturing units earlier this year by the US Food and Drug Administration, according to documents reviewed by FE. Natco, which was in news for battling Teva Pharmaceutical Industries over the patent of the latter's multiple sclerosis drug Copaxone, was issued the Form 483 dated May 23 after a five-day inspection of its finished dosage facility located in Mahabubnagar district in Telangana.

    Comment?

  5. Eagle Pharmaceuticals Announces That Teva Requests a Motion to...Read the original story

    17 hrs ago | Freshnews

    Eagle Pharmaceuticals, Inc. announced today that Cephalon, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., has moved to dismiss with prejudice its first lawsuit alleging that Eagle's tentatively approved bendamustine hydrochloride injection infusion product infringes one of its patents, U.S. Patent No. 8,445,524.

    Comment?

  6. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    17 hrs ago | Business Wire

    ... Pharmaceuticals, Inc. (NASDAQ:EGRX) announced today that Cephalon, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., has moved to dismiss with ... )--FUND A db x-trackers StoxxA Europe 600 Banks Short Daily UCITS ETF DEALING DATE A ...

    Comment?

  7. Indian stock market and companies daily reportRead the original story

    Yesterday | Stock Market Review

    ... drug product (RLD), Amoxicillin for Oral Suspension, 125mg/5mL and 250mg/5mL respectively of Teva Pharmaceutical Industries Ltd and indicated in the treatment of infections due to susceptible Betalactamase-negative strains of the designated ...

    Comment?

  8. 3 Reasons Dividend Stock Teva Pharmaceutical Industries Ltd. Could FallRead the original story

    Tuesday | The Motley Fool

    This rising tide among generic drug manufacturers is due mainly to the ongoing patent cliff, which has opened up a diversity of new opportunities for these companies. Even so, the rapid rise of this group of stocks has in some cases out-paced their underlying fundamentals, especially from a top-line growth perspective.

    Comment?

  9. OncoGenex Announces Completion of Patient Enrollment in the Phase 3...Read the original story

    Tuesday | Canada NewsWire

    ... of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug ...

    Comment?

  10. Here's Why You May Be Better Off Taking Generic Cholesterol DrugsRead the original story w/Photo

    Monday Sep 15 | Time

    A new study in the Annals of Internal Medicine found that the cost difference between generic and brand-name drugs seems to be a big factor when it comes to sticking with a medication-especially when it comes to statins, one of the most-prescribed drugs in the country. People who got the generic versions of the cholesterol-lowering medication were more likely to consistently take it and avoid cardiovascular disorders than those who filled the brand-name kind.

    Comment?

  11. Teva Canada Announces the Launch of (Pr)Teva-Ezetimibe, a Generic of (Pr)EzetrolRead the original story

    Jul 10, 2014 | Canada NewsWire

    /CNW/ - Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced today that Health Canada has approved its application for the generic version of PrEzetrolA in patients with primary (heterozygous familial and non-familial) ...

    Comment?

  12. 3 Reasons Actavis plc Stock Could FallRead the original story

    Monday Sep 15 | The Motley Fool

    ... basis, for instance, Actavis shares are trading at twice that of its generic-drug maker peer Teva Pharmaceutical Industries ( 12-month revenue, while Teva's are closer to only three times. All told, Actavis looks overvalued; it will need to live up ...

    Comment?

  13. Antares Pharma Announces Promotion of Robert F. Apple to Chief Operating OfficerRead the original story

    Monday Sep 15 | Business Wire

    ... multi-use pen injectors and reusable needle-free injectors marketed as TjetA and ZomajetA by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that ...

    Comment?

  14. Another Israel Pharmaceutical Firm Goes to NASDAQRead the original story w/Photo

    Oct 9, 2013 | The Jewish Press

    Kitov Pharmaceuticals accounted it plans to apply for listing on the NASDAQ exchange, joining Israel-based Teva and Kamada that are traded on Wall Street. Kitov is hoping for approval from the U.S. Food and Drug Administration after its Phase III clinical trial of a combination drug for the treatment of hypertension and pain relief.

    Comment?

  15. Teva Pharmaceutical Is Poised To GrowRead the original story w/Photo

    Saturday Sep 13 | Seeking Alpha

    ... High Court paving the way for the company to launch its DuoResp Spiromax inhaler in the UK. Teva Pharmaceutical Industries Limited (NYSE: TEVA ) develops, manufactures, and markets generic, branded and OTC medicines. Teva Pharmaceutical is the ...

    Comment?

  16. Sanofi aims to grow Genzyme unit with new drugs and acquisitionsRead the original story

    Saturday Sep 13 | Reuters

    ... most common form of the disease, in a market dominated by rivals Biogen Idec, Novartis and Teva Pharmaceutical Industries. Lemtrada is already sold in Europe but has yet to be approved in the United States, where experts have raised questions about ...

    Comment?

  17. Teva Presents New Clinical Safety Data in RRMS Patients Treated with...Read the original story

    Friday Sep 12 | Freshnews

    JERUSALEM & LUND, Sweden -- -- Teva Pharmaceutical Industries Ltd. and Active Biotech today announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis who were treated with laquinimod in Phase II, Phase III and open-label extension studies for two or more years. The pooled safety analysis of the Phase II LAQ/5063 and the Phase III ALLEGRO and BRAVO extension studies supports findings observed in the core studies where currently identified risks were observed within the first months of laquinimod treatment.

    Comment?

  18. Teva Presents Gene Expression Analysis at Joint Actrims-Ectrims...Read the original story

    Friday Sep 12 | Business Wire

    Teva Pharmaceutical Industries Ltd., today announced that new scientific data presented at the MS Boston 2014: Joint ACTRIMS-ECTRIMS Meeting reveals differences in the gene expression profile between COPAXONEA and other glatiramer acetate products. "For more than 20 years, Teva has manufactured COPAXONEA through its proprietary manufacturing process to ensure batches meet the same specification standards."

    Comment?

  19. Teva presents new clinical safety data in RRMS patients treated with LaquinimodRead the original story

    Tuesday Sep 2 | Theflyonthewall.com

    ... Buy rating on Medidata. Teva reports statistically significant results in reslizumab trial Teva Pharmaceutical Industries announced that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving ...

    Comment?

  20. Teva to present Copaxone gene expression analysisRead the original story

    Tuesday Sep 2 | Theflyonthewall.com

    ... Buy rating on Medidata. Teva reports statistically significant results in reslizumab trial Teva Pharmaceutical Industries announced that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving ...

    Comment?